What is UBT251 (Vistrutide)?
UBT251 is an investigational peptide that activates GLP-1, GIP and glucagon receptors. The catalog also uses the name Vistrutide; the cited primary trial reports the agent as UBT251 and does not independently establish that alias or a commercial product's identity.
Mechanism & research focus
Its development combines three hormone-receptor pathways involved in nutrient handling and energy balance. Receptor agonism describes the investigational molecule, not a verified potency result for a listed vial.
What the research covers
An October 2026 phase 2 publication reported a randomized placebo-controlled trial in 205 adults with overweight or obesity without type 2 diabetes. Over 24 weeks, UBT251 groups had greater mean weight reduction than placebo, alongside changes in cardiometabolic measures. Gastrointestinal symptoms were common adverse events.
What remains uncertain
A relatively short phase 2 study cannot establish long-term clinical outcomes or comprehensive safety. Results depend on the trial population and controlled preparation. The publication is not evidence that a research vial is interchangeable with the trial product.
The evidence label describes the linked research, not the suitability of a catalog product for use in people. Formulation, identity, purity, and measured content must be assessed separately.
Sources & studies
UBT251 in adults with overweight or obesity: a randomized phase 2 trial ↗
205 participants; 24-week trial of GLP-1/GIP/glucagon triple agonism, registered as NCT07177469.
Read the full paper for its design, controls and limitations. A source link is not a claim that its tested material matches a DA formulation.
Catalog formats & documentation
Formats grouped by compound identity. Availability and batch documentation remain on Disguised Alpha.